Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

762.20 +2.07 (+0.27%)
Streaming Delayed Price Updated: 11:08 AM EDT, Sep 18, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Novo Nordisk Pops 8% On 'Significant' Weight Loss For Oral Wegovy
Novo Nordisk stock surged Thursday after its oral version of Wegovy helped patients lose a "significant" amount of weight. 
Via Investor's Business Daily
Novo Nordisk's Wegovy Outperforms Eli Lilly's Tirzepatide In Reducing Risk Of Heart Attack, Stroke, And Death: Study
Novo Nordisk's Wegovy cut cardiovascular risks more than tirzepatide in real-world data from patients with obesity and heart disease. 
Via Benzinga
Why Is Everyone Talking About Novo Nordisk Stock?
Competition in various directions is affecting the company's fastest-growing product. 
Via The Motley Fool
3 Dividend Growth Stocks You Can Buy and Forget About
These stocks have been raising their payouts for years and they're likely going to continue doing so for the foreseeable future. 
Via The Motley Fool
Topics Economy
Krispy Kreme Jumps After Hours Following Kash Patel's Stake Reveal
Krispy Kreme's stock rose 3.81% after hours on Wednesday, following FBI Director Kash Patel's testimony about his stock purchase, despite a 68.28% drop in 2025. 
Via Benzinga
Eli Lilly Says Its Obesity Pill Topped Novo Nordisk’s Oral Drug In Late-Stage Diabetes Trial
Via Stocktwits
Why Is Eli Lilly’s Stock Slipping Premarket?
Via Stocktwits
1 Mega-Cap Stock with Impressive Fundamentals and 2 We Question
"Too big to fail" is how we would describe the megacap stocks in this article today. While they will likely stand the test of time, it’s not all sunshine and rainbows as their scale can limit their... 
Via StockStory
Topics Artificial Intelligence
Novo Nordisk Stock Jumps After-Hours On Wegovy Pill Breakthrough As Weight-Loss War With Eli Lilly Heats Up
The Danish drugmaker has already filed the once-daily pill with U.S. regulators, aiming for the first FDA-approved oral GLP-1 treatment for obesity. 
Via Stocktwits
FBI Director Kash Patel Bought 2 Stocks In 2025 — One's Already A Meme Favorite
FBI Director Kash Patel was asked about two stocks he bought earlier this year by a member of Congress on Wednesday and gave a surprising answer. The transactions come as members of Congress are... 
Via Benzinga
Why Novo Nordisk Stock Popped Today
Novo Nordisk lost half its value over the past year. Is it cheap enough to buy now? 
Via The Motley Fool
Eli Lilly To Set Up $5B Facility In Virginia – More Details Inside
Via Stocktwits
Congressional Trading Report: Rep. David Taylor Sold Over $2K In Alphabet Stock
 
Via Benzinga
GSK To Pour $30 Billion Into US R&D, Manufacturing Over Five Years
GSK will invest $30 billion in U.S. R&D and manufacturing, including a new biologics factory, AI upgrades, and expanded drug and device capabilities. 
Via Benzinga
Topics Artificial Intelligence
Could This Eli Lilly Oral Pill Be Key To Significant Weight Loss?
Eli Lilly's orforglipron showed significant weight loss, improved blood sugar, and reduced inflammation in adults with obesity or overweight in a Phase 3 trial. 
Via Benzinga
Apple To Rally More Than 28%? Here Are 10 Top Analyst Forecasts For Wednesday
 
Via Benzinga
This FedEx Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday
 
Via Benzinga
Dow Futures Stall Ahead Of Fed’s Interest Rate Decision Today: WDAY, MSFT, GOOGL, NVDA Among Stocks To Watch
While Dow Jones futures were up 0.03% at the time of writing, the S&P 500 futures fell 0.07%. 
Via Stocktwits
Topics ETFs Economy Government
GSK Stock Climbs After-Hours On $30B US Investment Pledge As Trump Pressures Big Pharma To Build In America
The plan includes $1.2 billion for a new biologics factory in Upper Merion, Pennsylvania, along with AI upgrades and expanded drug production across existing U.S. sites. 
Via Stocktwits
Topics Artificial Intelligence Government World Trade
Why Eli Lilly Stock Was a Winner Today
A news article implied that the company might have an advantage in the weight loss drug race. 
Via The Motley Fool
Novo Nordisk Navigates a GLP-1 Gold Rush: Soaring Obesity Drug Sales Clash with Revised Outlook Amidst Mounting Competition
Copenhagen, Denmark – Pharmaceutical giant Novo Nordisk (NYSE: NVO) has reported a robust second quarter for 2025, with impressive revenue and net income figures largely propelled by the formidable... 
Via MarketMinute
Topics Earnings Economy Intellectual Property
FDA Flags Eli Lilly's Weight-Loss Drug Video For Misleading Claims
The FDA finds Eli Lilly's video on Zepbound and Mounjaro misleading, citing omissions of serious risks. 
Via Benzinga
Eli Lilly To Invest $5 Billion In New Virginia Manufacturing Facility To Support Cancer Drugs Manufacturing
Eli Lilly plans a $5 billion Virginia facility to expand drug production, create 650 jobs, and use advanced tech for cancer and autoimmune treatments. 
Via Benzinga
Wegovy's Next Step: Novo Nordisk Eyes Approval for Higher-Dose Treatment
Novo Nordisk plans to seek FDA approval for a high-dose Wegovy, matching Eli Lilly's Zepbound with another weight-loss option for patients. 
Via Benzinga
3 Undervalued Healthcare Stocks to Buy Now While They're Cheap
In an otherwise hot stock market, healthcare stocks are underperforming. 
Via The Motley Fool
Forecasting The Future: 10 Analyst Projections For Eli Lilly
 
Via Benzinga
3 Great High-Yield Dividend Stocks to Buy in September
Quality yields above 6% from three very different market sectors. 
Via The Motley Fool
Here Is My Top Stock Pick Among the Weight Loss Industry Leaders
The weight loss drug market may reach $95 billion within five years. 
Via The Motley Fool
Novo Nordisk's Weight-Loss Wonders Drive Q2 Growth Amidst Shifting Sands of Competition
Novo Nordisk (NYSE: NVO) has once again demonstrated formidable strength in its obesity care segment, with powerhouse drugs Wegovy and Ozempic propelling the company to a robust Q2 2025 performance.... 
Via MarketMinute
Topics Economy Intellectual Property
AstraZeneca Puts Cambridge Expansion On Ice Adding Pressure On Starmer Ahead Of Trump Visit
AstraZeneca pauses its £200 million UK investment as rising costs, undervaluation, and unclear policies hinder pharma R&D and foreign capital inflows. 
Via Benzinga
Topics Government
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.